Pamela M. Pollock

7.1k total citations · 1 hit paper
90 papers, 4.0k citations indexed

About

Pamela M. Pollock is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Pamela M. Pollock has authored 90 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 31 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Pamela M. Pollock's work include Fibroblast Growth Factor Research (27 papers), Cancer Genomics and Diagnostics (18 papers) and Endometrial and Cervical Cancer Treatments (17 papers). Pamela M. Pollock is often cited by papers focused on Fibroblast Growth Factor Research (27 papers), Cancer Genomics and Diagnostics (18 papers) and Endometrial and Cervical Cancer Treatments (17 papers). Pamela M. Pollock collaborates with scholars based in Australia, United States and United Kingdom. Pamela M. Pollock's co-authors include Nicholas K. Hayward, Sara A. Byron, Michael G. Gartside, Paul J. Goodfellow, Paul S. Meltzer, Jeffrey M. Trent, Matthew A. Powell, William D. Foulkes, Candice L. Wellens and John V. Pearson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Pamela M. Pollock

86 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

2015 341 citations Tjalling Bosse, Helen Mackay et al. profile →

Peers

Countries citing papers authored by Pamela M. Pollock

Since Specialization

Citations

This map shows the geographic impact of Pamela M. Pollock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela M. Pollock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela M. Pollock more than expected).

Fields of papers citing papers by Pamela M. Pollock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela M. Pollock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela M. Pollock. The network helps show where Pamela M. Pollock may publish in the future.

Co-authorship network of co-authors of Pamela M. Pollock

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela M. Pollock. A scholar is included among the top collaborators of Pamela M. Pollock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela M. Pollock. Pamela M. Pollock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Félix Blanc‐Durand, (unknown), Etienne Rouleau, Antoine Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, (unknown), (unknown), Natalie Y.L. Ngoi, David S.P. Tan, Alexandra Léary	0
2	788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Annals of Oncology ·Félix Blanc‐Durand, Christopher M. Kramer, Etienne Rouleau, Damien Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, Natalie Y.L. Ngoi, (unknown), (unknown), David S.P. Tan, Alexandra Léary	0
3	FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes 2020 ·Clinical Cancer Research ·(unknown), Ann‐Marie Patch, Cameron Snell, Deborah S. Smith, Samuel Leung, Aline Talhouk, Elizabeth D. Williams, Jessica N. McAlpine, Pamela M. Pollock	14
4	Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts 2019 ·Biomaterials ·Ali Shokoohmand, Jiongyu Ren, Jeremy Baldwin, (unknown), Abbas Shafiee, Christina Theodoropoulos, Marie‐Luise Wille, Phong A. Tran, Laura J. Bray, Deborah S. Smith, Naven Chetty, Pamela M. Pollock, Dietmar W. Hutmacher, Judith A. Clements, Elizabeth D. Williams, Nathalie Bock	31
5	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers 2017 ·Molecular Cancer Therapeutics ·Leisl Packer, (unknown), Vanessa Bonazzi, Robert J. Ju, (unknown), Margaret C. Cummings, Sally‐Anne Stephenson, Pamela M. Pollock	32
6	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition 2017 ·Data Archiving and Networked Services (DANS) ·Florine A. Eggink, Inge C. van Gool, Alexandra Léary, Pamela M. Pollock, Emma J. Crosbie, Linda Mileshkin, Ekaterina S. Jordanova, Julien Adam, Luke Freeman-Mills, David N. Church, Carien L. Creutzberg, Marco de Bruyn, Hans W. Nijman, Tjalling Bosse	17
7	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study 2017 ·Gynecologic Oncology ·Y. Jeske, Shamshad Ali, Sara A. Byron, Feng Gao, Robert S. Mannel, Rahel Ghebre, Paul DiSilvestro, Shashikant Lele, Michael L. Pearl, Amy P. Schmidt, Heather A. Lankes, Nilsa C. Ramirez, Golnar Rasty, Matthew A. Powell, Paul J. Goodfellow, Pamela M. Pollock	41
8	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma 2015 ·QUT ePrints (Queensland University of Technology) ·Mitchell Stark, Vanessa Bonazzi, Glen M. Boyle, Jane M. Palmer, Judith Symmons, Catherine Lanagan, Christopher Schmidt, Adrian C. Herington, Robert Ballotti, Pamela M. Pollock, Nicholas K. Hayward	1
9	Targeting mutant fibroblast growth factor receptors in cancer 2011 ·Trends in Molecular Medicine ·Heidi Greulich, Pamela M. Pollock	6
10	FGFR2 mutations are rare across histologic subtypes of ovarian cancer 2010 ·Gynecologic Oncology ·Sara A. Byron, Michael G. Gartside, Candice L. Wellens, Paul J. Goodfellow, Michael J. Birrer, Ian Campbell, Pamela M. Pollock	37
11	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes 2009 ·Cancer Research ·Chelsea C. Pinnix, John Tayu Lee, Zhaojun Liu, (unknown), Klara Balint, Levi J. Beverly, Patricia Brafford, Min Xiao, Benjamin Himes, Susan E. Zabierowski, Yumi Yashiro–Ohtani, Katherine L. Nathanson, (unknown), Pamela M. Pollock, Ashani T. Weeraratna, Brian J. Nickoloff, Warren S. Pear, Anthony J. Capobianco, Meenhard Herlyn	94
12	Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma 2009 ·Molecular Cancer Research ·Michael G. Gartside, Huaibin Chen, Omar A. Ibrahimi, Sara A. Byron, (unknown), Candice L. Wellens, (unknown), Laura M. Yudt, Anna V. Eliseenkova, Jinghong Ma, John A. Curtin, (unknown), Ursula L. Harper, Erica L. Riedesel, Graham J. Mann, Jeffrey M. Trent, Boris C. Bastian, Paul S. Meltzer, Moosa Mohammadi, Pamela M. Pollock	102
13	Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation 2008 ·Cancer Research ·Sara A. Byron, Michael G. Gartside, Candice L. Wellens, Mary A. Mallon, (unknown), Matthew A. Powell, Paul J. Goodfellow, Pamela M. Pollock	119
14	Inhibition of FGFR2 in endometrial cancer cells induced apoptosis despite constitutive activation of the PI3K/AKT pathway. 2007 ·Molecular Cancer Therapeutics ·Michael G. Gartside, Sara A. Byron, Candice L. Wellens, (unknown), Matthew A. Powell, Paul J. Goodfellow, Pamela M. Pollock	1
15	Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells 2005 ·Cancer Research ·Jian‐Zhong Qin, (unknown), Lawrence Stennett, Barbara Bodner, Brian K. Bonish, Vijaya Chaturvedi, Frank Bennett, Pamela M. Pollock, Jeffrey M. Trent, Mary J.C. Hendrix, Paola Rizzo, Lucio Miele, Brian J. Nickoloff	263
16	Identification of FGFR2 as a novel melanoma oncogene 2005 ·Cancer Research ·Michael G. Gartside, (unknown), Laura M. Yudt, Ursula L. Harper, (unknown), Sandra Pavey, Ralph J. Tuthill, Boris C. Bastian, Paul S. Meltzer, Pamela M. Pollock	1
17	Notch and NOXA-Related Pathways in Melanoma Cells 2005 ·Journal of Investigative Dermatology Symposium Proceedings ·Brian J. Nickoloff, Mary J.C. Hendrix, Pamela M. Pollock, Jeffrey M. Trent, Lucio Miele, Jian‐Zhong Qin	50
18	Microarray expression profiling in melanoma reveals a BRAF mutation signature 2004 ·Oncogene ·Sandra Pavey, Peter A. Johansson, Leisl Packer, Jennifer M. Taylor, Mitchell Stark, Pamela M. Pollock, Graeme J. Walker, Glen M. Boyle, Ursula L. Harper, Sarah‐Jane Cozzi, Katherine Hansen, Laura M. Yudt, Christopher Schmidt, Peter Hersey, K.A.O. Ellem, Michael G. E. OʼRourke, Peter G. Parsons, Paul Meltzer, Markus Ringnér, Nicholas K. Hayward	136
19	A genome-based strategy uncovers frequent BRAF mutations in melanoma 2002 ·Cancer Cell ·Pamela M. Pollock, Paul S. Meltzer	116
20	The CDKN2A (p16) gene and human cancer 1997 ·QUT ePrints (Queensland University of Technology) ·William D. Foulkes, (unknown), Pamela M. Pollock, Nicholas K. Hayward	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact